Nanobiotix (NBTX) Competitors

CureVac (NASDAQ:CVAC) and Nanobiotix (NASDAQ:NBTX) are both small-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their institutional ownership, earnings, media sentiment, valuation, dividends, profitability, risk, analyst recommendations and community ranking.

Do analysts prefer CVAC or NBTX?

CureVac presently has a consensus price target of $10.00, indicating a potential upside of 220.51%. Nanobiotix has a consensus price target of $8.00, indicating a potential upside of 139.52%. Given CureVac's higher possible upside, analysts plainly believe CureVac is more favorable than Nanobiotix.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
CureVac	0 Sell rating(s)	2 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.33
Nanobiotix	0 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.67

Does the MarketBeat Community believe in CVAC or NBTX?

CureVac received 14 more outperform votes than Nanobiotix when rated by MarketBeat users. However, 63.16% of users gave Nanobiotix an outperform vote while only 55.32% of users gave CureVac an outperform vote.

Company	Underperform	Outperform
CureVac	Outperform Votes 26 55.32%	Underperform Votes 21 44.68%
Nanobiotix	Outperform Votes 12 63.16%	Underperform Votes 7 36.84%

Is CVAC or NBTX more profitable?

CureVac has a net margin of 20.72% compared to Nanobiotix's net margin of 0.00%. CureVac's return on equity of 21.98% beat Nanobiotix's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
CureVac	20.72%	21.98%	15.72%
Nanobiotix	N/A	N/A	N/A

Does the media prefer CVAC or NBTX?

In the previous week, CureVac had 7 more articles in the media than Nanobiotix. MarketBeat recorded 9 mentions for CureVac and 2 mentions for Nanobiotix. CureVac's average media sentiment score of 0.25 beat Nanobiotix's score of 0.00 indicating that CureVac is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
CureVac	3 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral
Nanobiotix	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Which has more risk & volatility, CVAC or NBTX?

CureVac has a beta of 2.48, indicating that its share price is 148% more volatile than the S&P 500. Comparatively, Nanobiotix has a beta of 0.26, indicating that its share price is 74% less volatile than the S&P 500.

Which has better valuation & earnings, CVAC or NBTX?

Nanobiotix has lower revenue, but higher earnings than CureVac.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
CureVac	$543.28M	1.29	-$281.58M	$0.82	3.80
Nanobiotix	-$11.61M	-13.56	-$42.97M	N/A	N/A

Do insiders & institutionals have more ownership in CVAC or NBTX?

17.3% of CureVac shares are owned by institutional investors. Comparatively, 38.8% of Nanobiotix shares are owned by institutional investors. 2.2% of CureVac shares are owned by company insiders. Comparatively, 3.5% of Nanobiotix shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Summary

CureVac beats Nanobiotix on 10 of the 16 factors compared between the two stocks.